global Point Of Care
Your Rapid Respiratory Testing Solutions
Respiratory infection symptoms can be misleading, and can result in misdiagnosis, unnecessary tests, overuse of antimicrobials, and the continued spread of an infection throughout the community. When you need to diagnose a respiratory infection, you shouldn’t have to choose between speed and accuracy. With the help of rapid respiratory testing solutions from Abbott, practitioners can quickly and accurately determine whether respiratory infections are self-limiting or require therapy. That can contribute to better treatment strategies, improved patient outcomes, and lower costs.
The sooner you know results, the more effectively you can manage respiratory care.
Respiratory infections pose a two-pronged threat to human health. Failure to treat patients quickly and appropriately could result in outbreaks and epidemics, while overuse of antibiotics can spur the emergence of antimicrobial-resistant infections.1, Abbott's best-in-class respiratory products can help practitioners define appropriate treatment strategies fast, thus facilitating:
- Improved patient and bed management during respiratory season
- Reduced spread of nosocomial infections
- Targeted treatment decisions, for better antimicrobial stewardship
- Elimination of costly extra tests
The ID NOW™ rapid, molecular testing platform provides results in minutes for COVID-19, Influenza A & B, RSV and Strep A.
Our Respiratory Testing Products
Rely on the market leader in rapid respiratory diagnostics.
We're a world leader in point-of-care testing2, offering an unmatched range of rapid respiratory point-of-care options. Our high-performance solutions help clinicians identify pathogens immediately and accurately, so they can determine appropriate treatment strategies sooner.
Molecular Innovation
Bringing next-generation molecular technology to the point of care
Detecting the molecular signature (i.e., DNA) of a harmful organism at the point of care is fast becoming the most accurate and rapid way to identify infectious diseases, so that healthcare professionals can quickly initiate the correct course of therapy. However, most molecular tests rely on lab-based thermo cycling, which can slow time to treatment.
That’s why Abbott created the ideal molecular platform for POC. ID NOW™ combines the benefits of speed and accuracy. You no longer need to compromise when testing your patients and making clinical decisions. A rapid molecular result with ID NOW™ means no longer having to choose. It provides accurate results in just minutes, so you can make immediate, appropriate clinical decisions.
Improved Patient Management
Fast diagnosis, fast treatment
Rapid testing allows clinicians to make actionable treatment decisions for highly contagious respiratory infectious diseases right at the point of care, while patients wait. Rapid molecular and antigen tests can enhance clinical confidence and influence decisions for improved workflow and timely patient management, leading to healthier outcomes.
Control Infection Sooner
Prompt diagnosis is key to preventing cross-infection and outbreaks
Clinicians often have to make immediate treatment decisions based only on signs and symptoms due to poor access to sensitive, rapid diagnostic tests and long turnaround times for laboratory PCR results. If a contagious respiratory infection isn’t diagnosed in time, the health consequences can be dire for a community.
That’s why Abbott's respiratory solutions are designed to enable immediate diagnosis, right at the point of care. Our tests help you make real-time decisions on infection control and patient cohorting, so you can help reduce the risk of further infection of patients, medical staff, and others in the community.3
Combat Antimicrobial Resistance
Make targeted treatment decisions earlier with POC testing
Over-prescription of antibiotics has led to a global health crisis. Microbes are developing immunity to medications that used to kill them. As a result, a growing number of infections are becoming harder to treat.
Rapid diagnostic tests are increasingly seen as vital to reducing antibiotic over-use.4 Abbott is leading the way. Our breakthrough, best-in-class rapid diagnostics help practitioners quickly determine which respiratory tract infections (RTIs) require treatment, and which ones are self-limiting. By identifying pathogens at the point of care, you can make targeted treatment decisions sooner — reducing inappropriate antimicrobial use and the spread of resistance.
EXPAND YOUR KNOWLEDGE
View References
- World Health Organization (WHO). Antimicrobial resistance fact sheet. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Updated November 21, 2023. Accessed August 29, 2024.
- Abbott. Data on File.
- World Health Organization (WHO). Use of Influenza Rapid Diagnostic Tests. 1 January 2010. https://www.who.int/publications/i/item/9789241599283. Accessed on 24 April, 2024.
- The Review on Antimicrobial Resistance: Tackling drug-resistant infections globally: Final report and recommendations. May 2016. https://amr-review.org/Publications.html. Accessed August 29, 2024.
